ACIU AC Immune SA

8.91
-0.15  -2%
Previous Close 9.06
Open 9.05
Price To book 3.85
Market Cap 507.18M
Shares 56,922,000
Volume 23,561
Short Ratio 13.23
Av. Daily Volume 49,358

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Second Phase 3 trial initiation announced February 28, 2017.
Crenezumab - CREAD 2
Alzheimer’s disease
Phase 2 trial to commence 2017. IPO September 23, 2016.
ACI-35 (anti-tau vaccine)
Alzheimer’s disease
Phase 1/2 ongoing. IPO September 23, 2016. Decision on future trials due within next few months - as of March 17, 2017.
ACI-24 (anti-Abeta vaccine)
Alzheimer’s disease
Phase 3 trial commennced 1Q 2016. Phase 2 trial did not meet co-primary endpoints. IPO September 23, 2016. Data due 2020.
Crenezumab - CREAD 1
Alzheimer’s disease

Latest News

  1. AC IMMUNE AND ESSEX BIO-TECHNOLOGY ANNOUNCE RESEARCH COLLABORATION FOR NEURODEGENERATIVE DISEASES AND NEUROINFLAMMATION
  2. AC Immune reports 1Q loss
  3. AC IMMUNE SA REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS
  4. Piramal Imaging and AC Immune present first clinical data for tau PET-imaging tracer at International Alzheimer's Conference
  5. AC Immune SA :ACIU-US: Earnings Analysis: Q4, 2016 By the Numbers : March 23, 2017
  6. AC IMMUNE PROVIDES TWELVE UPDATES ON ITS PIPELINE AT THE INTERNATIONAL CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASES
  7. AC IMMUNE REPORTS FULL YEAR 2016 FINANCIAL RESULTS AND R&D UPDATE
  8. AC Immune SA breached its 50 day moving average in a Bearish Manner : ACIU-US : March 7, 2017
  9. Roche to start new trial of AC Immune drug against Alzheimer's
  10. AC IMMUNE PARTNER GENENTECH TO START SECOND PHASE 3 CLINICAL TRIAL FOR ALZHEIMER'S THERAPY CRENEZUMAB
  11. AC Immune SA breached its 50 day moving average in a Bullish Manner : ACIU-US : January 16, 2017
  12. AC Immune SA – Value Analysis (NASDAQ:ACIU) : December 23, 2016
  13. AC Immune SA breached its 50 day moving average in a Bearish Manner : ACIU-US : December 22, 2016
  14. Here is What Hedge Funds Think About AC Immune Ltd (ACIU)
  15. AC Immune SA breached its 50 day moving average in a Bullish Manner : ACIU-US : December 12, 2016
  16. Astra, Lilly stick with Alzheimer's approach despite setback
  17. AC Immune SA :ACIU-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016
  18. Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know
  19. Alzheimer's Remains a Top Priority for Big Pharma